Author Correction: Pre-therapeutic efficacy of the CDK inhibitor dinaciclib in medulloblastoma cells

Author Correction: Pre-therapeutic efficacy of the CDK inhibitor dinaciclib in medulloblastoma cells

Saved in:

Bibliographic Details
Main Authors:	Marta Buzzetti, Sonia Morlando, Dimitrios Solomos, Ammara Mehmood, Alexander W. I. Cox, Mattia Chiesa, Yuri D’Alessandra, Michela Garofalo, Caroline H. Topham, Gianpiero Di Leva
Format:	Article
Language:	English
Published:	Nature Portfolio 2025-02-01
Series:	Scientific Reports
Online Access:	https://doi.org/10.1038/s41598-024-83271-0
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Pre-therapeutic efficacy of the CDK inhibitor dinaciclib in medulloblastoma cells
by: Marta Buzzetti, et al.
Published: (2021-03-01)

Clinical case – medulloblastoma
by: A. Kablytė, et al.
Published: (2018-03-01)

A case of adult medulloblastoma
by: Zhihan Sun, et al.
Published: (2025-02-01)

Comparative analysis of pediatric SHH medulloblastoma DAOY spheres and adherent monolayers: implications for medulloblastoma research
by: Jana Klementová, et al.
Published: (2025-01-01)

Author Correction: Multi-omic and single-cell profiling of chromothriptic medulloblastoma reveals genomic and transcriptomic consequences of genome instability
by: Petr Smirnov, et al.
Published: (2025-01-01)

Perivascular space imaging during therapy for medulloblastoma.
by: Ruitian Song, et al.
Published: (2025-01-01)

MicroRNAs-Proteomic Networks Characterizing Human Medulloblastoma-SLCs
by: Giuseppina Catanzaro, et al.
Published: (2016-01-01)

Modulation of Stemness and Differentiation Regulators by Valproic Acid in Medulloblastoma Neurospheres
by: Natália Hogetop Freire, et al.
Published: (2025-01-01)

CDK14 regulates the development and repair of lung
by: Jian-wei Chen, et al.
Published: (2025-01-01)

Mapping naturally presented T cell antigens in medulloblastoma based on integrative multi-omics
by: Julia Velz, et al.
Published: (2025-02-01)

Alpha/beta values in pediatric medulloblastoma: implications for tailored approaches in radiation oncology
by: Danny Jazmati, et al.
Published: (2025-01-01)

Ferroptosis Transcriptional Regulation and Prognostic Impact in Medulloblastoma Subtypes Revealed by RNA-Seq
by: Christophe Desterke, et al.
Published: (2025-01-01)

Dual Inhibition of CDK4/6 and CDK7 Suppresses Triple‐Negative Breast Cancer Progression via Epigenetic Modulation of SREBP1‐Regulated Cholesterol Metabolism
by: Yilan Yang, et al.
Published: (2025-02-01)

Cdk6’s functions are critically regulated by its unique C-terminus
by: Alessia Schirripa, et al.
Published: (2025-02-01)

Suppressing recurrence in Sonic Hedgehog subgroup medulloblastoma using the OLIG2 inhibitor CT-179
by: Yuchen Li, et al.
Published: (2025-02-01)

Aberrant FGF signaling promotes granule neuron precursor expansion in SHH subgroup infantile medulloblastoma
by: Odessa R Yabut, et al.
Published: (2025-01-01)

OLIG2 mediates a rare targetable stem cell fate transition in sonic hedgehog medulloblastoma
by: Kinjal Desai, et al.
Published: (2025-02-01)

Multi-omic and single-cell profiling of chromothriptic medulloblastoma reveals genomic and transcriptomic consequences of genome instability
by: Petr Smirnov, et al.
Published: (2024-11-01)

Discrete vulnerability to pharmacological CDK2 inhibition is governed by heterogeneity of the cancer cell cycle
by: Vishnu Kumarasamy, et al.
Published: (2025-02-01)

Exploring adherence in patients with advanced breast cancer: focus on CDK4/6 inhibitors
by: Baković Matea, et al.
Published: (2023-12-01)

Ki-67 and CDK1 control the dynamic association of nuclear lipids with mitotic chromosomes
by: Hsiao-Tang Hu, et al.
Published: (2025-01-01)

LncRNA LOXL1-AS1 Promotes the Proliferation and Metastasis of Medulloblastoma by Activating the PI3K/AKT Pathway
by: Ran Gao, et al.
Published: (2018-01-01)

Enitociclib, a selective CDK9 inhibitor: in vitro and in vivo preclinical studies in multiple myeloma
by: Son Tran, et al.
Published: (2025-02-01)

The deleterious effects of CDK4/6 inhibition on renal recovery post-acute kidney injury
by: Shanshan Zhou, et al.
Published: (2024-11-01)

CDK1 mediates the metabolic regulation of DNA double-strand break repair in metaphase II oocytes
by: Tian-Jin Xia, et al.
Published: (2025-02-01)

Fluorine Substituted 1,2,4-Triazinones as Potential Anti-HIV-1 and CDK2 Inhibitors
by: Mohammed S. I. Makki, et al.
Published: (2014-01-01)

Regulation of the G1/S Transition in Hepatocytes: Involvement of the Cyclin-Dependent Kinase Cdk1 in the DNA Replication
by: Anne Corlu, et al.
Published: (2012-01-01)

Regulation of modular Cyclin and CDK feedback loops by an E2F transcriptionoscillator in the mammalian cell cycle
by: Orit Lavi, et al.
Published: (2011-03-01)

Single-Cell RNA Sequencing Reveals LEF1-Driven Wnt Pathway Activation as a Shared Oncogenic Program in Hepatoblastoma and Medulloblastoma
by: Christophe Desterke, et al.
Published: (2025-01-01)

Advancing treatment choices: CDK4/6 inhibitor switching in HR+/HER2- metastatic breast cancer
by: Paola Zagami, et al.
Published: (2025-02-01)

circ_0001588 Induces the Malignant Progression of Hepatocellular Carcinoma by Modulating miR-874/CDK4 Signaling
by: Xiaoyun Bin, et al.
Published: (2021-01-01)

RET inhibition overcomes resistance to combined CDK4/6 inhibitor and endocrine therapy in ER+ breast cancer
by: Charlotte K. Kindt, et al.
Published: (2025-01-01)

Validation of a hypomorphic variant in CDK13 as the cause of CHDFIDD with autosomal recessive inheritance through determination of an episignature
by: Jan Fischer, et al.
Published: (2025-01-01)

Publisher Correction: The deleterious effects of CDK4/6 inhibition on renal recovery post-acute kidney injury
by: Shanshan Zhou, et al.
Published: (2025-01-01)

Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i): Mechanisms of resistance and where to find them
by: L. Foffano, et al.
Published: (2025-02-01)

CXCR4 promotes tumor stemness maintenance and CDK4/6 inhibitors resistance in ER-positive breast cancer
by: Qiangfeng Shi, et al.
Published: (2025-01-01)

A phase I study of the CDK4/6 inhibitor ribociclib combined with gemcitabine in patients with advanced solid tumors
by: Aurora Norman, et al.
Published: (2025-01-01)

Identification and validation of CDK1 as a promising therapeutic target for Eriocitrin in colorectal cancer: a combined bioinformatics and experimental approach
by: Jiemiao Shen, et al.
Published: (2025-01-01)

Diagnostic potential of CDK1 and STAT1 in acute kidney injury associated with gastrointestinal cancers: a bioinformatics-based study
by: Qiuwan Wei, et al.
Published: (2025-01-01)

CDK4/6 inhibitors promote PARP1 degradation and synergize with PARP inhibitors in non-small cell lung cancer
by: Carlos M Roggero, et al.
Published: (2025-02-01)